This post was originally written in 2014 by Kendall Morgan and updated in 2022 by Lucie Wilson. Lucie is an Addgene co-op from Northeastern University.
There can be no doubt that CRISPR/Cas9 technology has been a breakthrough for the genome-editing field. It has the possibility to treat human genetic diseases, and several treatments are currently being tested in clinical trials. It is speeding the process of the discovery/development of genetic targets and RNA therapies. . In 2014, we wrote a blog post on CRISPR’s potential for monogenetic diseases, the bulk of which you can find below.